A Phase 3b Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

Trial Profile

A Phase 3b Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

Recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Aug 2018

At a glance

  • Drugs Elagolix (Primary) ; Estradiol/norethisterone (Primary)
  • Indications Uterine leiomyoma
  • Focus Therapeutic Use
  • Sponsors AbbVie
  • Most Recent Events

    • 31 Jan 2018 Planned End Date changed from 8 Sep 2021 to 16 May 2022.
    • 31 Jan 2018 Planned primary completion date changed from 8 Sep 2021 to 14 Jun 2021.
    • 29 Nov 2017 Planned End Date changed from 16 May 2022 to 8 Sep 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top